Drugs / anti-GD2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03242603 | Oct 2017 → Aug 2019 | neuroblastoma | National University Hospital, Singapore | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-03-03 | Orphan Australia | Results Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications serb.com ↗
Overall, naxitamab demonstrated statistically significant efficacy with a manageable safety profile. |
| 2025-03-03 | Y-mAbs Therapeutics | Results Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications ymabs.com ↗
Overall, naxitamab demonstrated statistically significant efficacy with a manageable safety profile. |
| 2024-01-17 | Partner Therapeutics, Inc. | Results Comprehensive Review Highlights Importance of Leukine® in Combination with Anti-GD2 Immunotherapy for Treatment of High-Risk Pediatric Neuroblastoma partnertx.com ↗
Leukine has been studied extensively in combination with dinutuximab and naxitamab leading to improved patient outcomes. |
| 2023-10-16 | Orphan Australia | Results Y-mAbs Announces Publication in Cancers serb.com ↗
In this study, early administration of naxitamab-based chemo-immunotherapy was shown to significantly improve long-term outcomes, addressing an important unmet need in the current treatment paradigm for this critical patient group. |
| 2023-10-16 | Y-mAbs Therapeutics | Results Y-mAbs Announces Publication in Cancers ymabs.com ↗
In this study, early administration of naxitamab-based chemo-immunotherapy was shown to significantly improve long-term outcomes, addressing an important unmet need in the current treatment paradigm for this critical patient group. |
| 2023-05-26 | Y-mAbs Therapeutics | Results Y-mAbs Announces Presentation of Naxitamab Data at ASCO ymabs.com ↗
Overall, the most common naxitamab related serious adverse events were hypotension, pain, urticaria, and bronchospasm. |
| 2023-04-18 | Y-mAbs Therapeutics | Results Y-mAbs Announces Presentation of Naxitamab data at AACR ymabs.com ↗ |
| 2022-05-26 | Orphan Australia | Results Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint serb.com ↗ |
| 2022-05-26 | Y-mAbs Therapeutics | Results Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint ymabs.com ↗
The primary endpoint was reached in the MSK phase 2 trial: Objective Response Rate (“ORR”) according to the International Neuroblastoma Response Criteria (“INRC”) of 30.6 |
| 2019-12-11 | Y-mAbs Therapeutics | Results Y-mAbs Announces Positive Naxitamab Frontline Data ymabs.com ↗
In terms of overall survival (“OS”), the naxitamab patients achieved an 86% OS at 24 months, compared to 84% OS for the competing anti-GD2 antibody. |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-GD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03242603 ↗ |
| Known as | ch14.18/CHO | “combination with anti-GD2 (ch14.18/CHO)” NCT03242603 ↗ |
| Action | Deplete | “The anti-GD2 antibody mediates neuroblastoma cell killing” NCT03242603 ↗ |